Merck Takes License to Protiva Tech to Settle Litigation Inherited from Sirna | GenomeWeb
Sirna Therapeutics, a subsidiary of Merck, and Protiva Biotherapeutics have settled their year-and-a-half old legal battle over a scuttled licensing deal for an siRNA delivery technology.
As part of the settlement, Merck has taken a non-exclusive license to the Protiva delivery technology. In exchange, Protiva will receive an undisclosed one-time payment and potential milestones and royalties, the companies said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.